Financial Advisor
NeoGenomics, Inc.
Debt Capital Markets
Senior Secured Credit Facility
Transaction Details
- On December 22, 2016, NeoGenomics, Inc. (Nasdaq: NEO) (“NeoGenomics”), closed on a new five year, $150 million senior secured credit facility, which includes a $75 million revolving loan and a$75 million term loan
- Amounts drawn under the new facility bear interest according to a pricing grid that is based on the ratio of debt to Adjusted EBITDA, currently equal to LIBOR + 300 basis points
- Proceeds from the facility were used to refinance existing debt, redeem Series A Redeemable Preferred Stock and for general corporate purposes
- Stephens Inc. acted as exclusive financial advisor in the transaction
- In December 2015, Stephens served as exclusive financial advisor to NeoGenomics, successfully raising $80 million of committed, fully underwritten debt to support their acquisition of Clarient
About the company
NeoGenomics, Inc. specializes in cancer genetic s testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for Physicians to help them diagnose and treat cancer. The Company's Pharma Services division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CLIA certified laboratories in Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Tampa and Fort Myers, Florida; Houston, Texas and Nashville, Tennessee. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States. For additional information about NeoGenomics, visit http://neogenomics.com/.
Sources: Publicly available information.
-
This material has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets or developments referred to in the material. Information included in the material was obtained from external sources which we consider reliable, but we have not independently verified such information and do not guarantee that it is accurate or complete. Such information is believed to be accurate on the date of issuance of the material. No subsequent publication or distribution of this material shall mean or imply that any such information or opinion remains current at any time after the stated date of the material. We do not undertake to advise you of any changes in any such information or opinion. Additional information is available upon request.